奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2024.02.005

摘要/Abstract

摘要： 目的探讨应用奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎(CHC)患者的疗效。方法 2020年1月～2022年1月我院收治的106例基因1b型CHC患者, 其中观察组53例接受奥比帕利联合达塞布韦治疗, 对照组53例接受达塞布韦单药治疗, 两组治疗持续12周。采用实时荧光定量RT-PCR法检测血清HCV RNA载量, 考核超快速病毒学应答(SRVR)、快速病毒学应答(RVR)、治疗结束病毒学应答(ETVR)和随访12周时持续病毒学应答(SVR)。结果观察组SRVR、RVR、ETVR和SVR分别为88.7%、94.3%、100.0%和100.0%, 显著高于对照组(67.9%、75.4%、83.0%和90.5%, P＜0.05);在治疗12 周结束时, 观察组血清ALT和AST水平分别为(30.8±4.6)U/L和(29.7±2.4)U/L, 均显著低于对照组【分别为(52.2±5.1)U/L和(48.1±3.6)U/L, P＜0.05】;在治疗期间, 观察组不良反应发生率为18.7%, 显著高于对照组的9.4%(P＜0.05)。结论应用奥比帕利联合达塞布韦治疗基因1b型CHC患者疗效确切, 可有效改善肝功能, 提高血清HCV RNA转阴率, 且安全性尚可。

关键词: 慢性丙型肝炎, HCV基因1b型, 奥比他韦, 帕立瑞韦, 利托那韦, 达塞布韦, 病毒学应答, 治疗

Abstract: Objective The aim of this study was to investigate the virological response of patients with genotype 1b infected chronic hepatitis C (CHC) to combination of ombitasvir and dasabuvir antiviral therapy. Methods A total of 106 patients with genotype 1b infected CHC were enrolled in our hospital between January 2020 and January 2022, 53 patients in the observation group were treated with ombitasvir and dasabuvir combination and other 53 patients in the control group were treated with dasabuvir alone. The antiviral regimen lasted for 12 weeks in the two groups. Serum HCV RNA load was detected by real-time fluorescence quantitative PCR, and the super rapid virological response (SRVR), rapid virological response (RVR), end of treatment virological response (ETVR) and sustained virological response (SVR) were recorded. Results The SRVR, RVR, ETVR and SVR in the observation group were 88.7%, 94.3%, 100.0% and 100.0%, all significantly higher than 67.9%, 75.4%, 83.0% and 90.5% (P<0.05) in the control; at the end of 12 week treatment, serum ALT and AST levels in the observation group were (30.8±4.6)U/L and (29.7±2.4)U/L, both significantly lower than in the control group; during the period of antiviral treatment, the incidence of untoward effects in the observation group was 18.7%, much higher than 9.4%(P＜0.05) in the control group. Conclusion The combination of ombitasvir and dasabuvir in the treatment of patients with genotype 1b infected CHC is efficacious, with high virological response and improved liver function tests and relatively good safety.

Key words: Hepatitis C, Genotype 1b, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, Virological response, Therapy

李兴泉, 杨春, 李诗源, 翁凯, 彭麟. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 177-180.

Li Xingquan, Yang Chun, Li Shiyuan, et al.. Virological response of patients with genotype 1b infected chronic hepatitis C to combination of ombitasvir and dasabuvir antiviral therapy[J]. Journal of Practical Hepatology, 2024, 27(2): 177-180.

参考文献

[1] Abu-Freha N, Mathew Jacob B, Elhoashla A, et al. Chronic hepatitis C: diagnosis and treatment made easy. Eur J Gen Pract, 2022,28(1):102-108.
[2] Lee HW, Lee H, Kim BK, et al. Cost-effectiveness of chronic hepatitis C screening and treatment. Clin Mol Hepatol, 2022,28(2):164-173.
[3] 束青华,张楠楠,葛勇胜.不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响.实用肝脏病杂志,2021,24(6):899-902.
[4] 陈卫兵,王小红,刘芳.基因1b型不同准种株丙型肝炎病毒核心蛋白对HepG2细胞生物学行为的影响.实用肝脏病杂志,2022,25(1):13-17.
[5] 谢志伟,章红艳,陆霭琪,等.奥比帕利联合达塞布韦治疗基因1b型慢性丙型病毒性肝炎患者的疗效与安全性分析.中华生物医学工程杂志,2021,27(4):380-385.
[6] Dietz C, Maasoumy B. Direct-acting antiviral agents for hepatitis C virus infection-from drug discovery to successful implementation in clinical practice. Viruses,2022,14(6):1325-1326.
[7] Baumert TF, Berg T, Lim JK, et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology, 2019,156(2):431-445.
[8] 徐欢,王广丽,董丹丹,等.聚乙二醇干扰素α-2a联合利巴韦林标准抗病毒治疗慢性丙型肝炎患者疗效再研究.实用肝脏病杂志,2022,25(4):500-503.
[9] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2015年更新版.实用肝脏病杂志,2016,19(4):ⅠⅩ-ⅩⅩⅤⅠ.
[10] 魏丽,刘博,赵楠,梁丽君.恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析.实用肝脏病杂志,2023,26(2):181-184.
[11] Airewele NE, Shiffman ML. Chronic hepatitis Bvirus in patients with chronic hepatitis C virus. Clin Liver Dis, 2021,25(4):817-829.
[12] 柴晓哲,朱霞峰,骆成林,等.泛基因型与特异基因型DAAs方案精准治疗基因1b型慢性丙型肝炎患者疗效对比分析.实用肝脏病杂志,2022,25(3):355-358.
[13] 周巍,陈蕾,张政,等.维持性血液透析患者丙型肝炎病毒的基因分型及感染的危险因素.中华肾脏病杂志,2022,38(1):29-31.
[14] 揭育胜,袁静,张晓红,等.奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究.中华肝脏病杂志, 2019, 27(2):123-127.
[15] Wei L, Huang YH. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther, 2019,17(5):311-325.
[16] 陈亚巍,王无瑕,陈景涛,等.奥比帕利联合达塞布韦治疗维持性血液透析患者合并丙型肝炎病毒感染有效性和安全性的研究.中华保健医学杂志,2020,22(2):162-164.
[17] Johnson PJ, Berhane S, Walker AJ, et al. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. J Viral Hepat, 2021,28(1):168-176.
[18] 韩宏艳,潘娟,蒋文平,等.3D方案治疗基因1b型低病毒载量慢性丙型肝炎患者应答疗效研究.实用肝脏病杂志,2021,24(5):689-692.
[19] 许海玲,秦刚,薛红,等.艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究.实用肝脏病杂志,2022,25(6):788-791.
[20] 孙皆齐,姜绍文,汪铮.应用艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎初治和经治患者效果对比研究.实用肝脏病杂志,2022,25(2):195-198.
[21] Hong CM, Liu CH, Su TH, et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. J Microbiol Immunol Infect, 2020,53(4):569-577.
[22] Stanciu C, Muzica CM, Girleanu I, et al. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother, 2021,22(13):1729-1741.

奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究^*

Virological response of patients with genotype 1b infected chronic hepatitis C to combination of ombitasvir and dasabuvir antiviral therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[2]	于欣欣, 付朝霞, 薛莉. 减量索磷布韦联合全量达卡他韦治疗终末期肾病合并急性丙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 181-184.
[3]	李尧, 梁健, 张春, 董静, 陈照林, 周旭, 娄方明, 杨小康, 刘波, 宋海燕. 恩替卡韦联合聚乙二醇干扰素-α2b治疗代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2024, 27(2): 226-229.
[4]	王红霞, 胥晓倩, 于明帅. 内镜下硬化剂治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者应用不同剂量羟考酮联合丙泊酚靶控输注麻醉效果研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 230-233.
[5]	万贵香, 李忠廉, 赵亚博, 梁微微, 杜辉, 宁振海, 周媛, 万亮. 恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 234-237.
[6]	肖潇, 盛云建. 内镜下曲张静脉套扎术联合经颈静脉肝内门体静脉分流术治疗肝硬化食管胃底静脉曲张破裂出血患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 238-241.
[7]	付彦爽, 陈晓丽, 付彦青, 冯静. MWA联合抗PD-1抗体治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 259-262.
[8]	杨帆, 杨军, 濮忠健, 胡雪星. TACE术后联合斑蝥酸钠维生素B6治疗原发性肝癌患者近期疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 263-266.
[9]	张亚龙, 胡冬梅, 赵晟, 孟海生. 超声引导下射频消融治疗小原发性肝癌疗效及死亡危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 271-274.
[10]	王秀香, 李海霞, 李辉, 王明月, 代树本, 于晓明. DEB-TACE序贯微波消融术治疗大原发性肝癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 283-286.
[11]	贾江坤, 余淼, 贾萌, 徐健, 王佳佳, 宋红霞, 申权, 薛焕洲, 陈旭晓. 腹腔镜辅助下血管瘤剥除术与解剖性肝切除术治疗巨大肝血管瘤疗效比较^*[J]. 实用肝脏病杂志, 2024, 27(2): 287-290.
[12]	何晓非, 陈杰, 罗国松, 陆世峰. ERCP治疗急性梗阻性化脓性胆管炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 291-294.
[13]	唐昊, 杨天福. 腹腔镜胆总管探查术联合经腹直肌引出T管与经右锁骨中线引出引流治疗胆总管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 295-298.
[14]	王卿, 栾娜, 叶刚. 经皮经肝I期胆道造瘘联合分步胆道镜治疗Roux-en-Y胆肠吻合术后结石复发的肝胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 299-302.
[15]	王兵, 肖元初, 孙振纲, 王帅. 倾向性评分匹配腹腔镜肝叶切除术与开腹术治疗合并肝硬化的肝胆管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 303-306.